How many insider trades does FilingIQ track for PMCB?

FilingIQ tracks 24 Form 4 insider transactions for PMCB (PharmaCyte Biotech, Inc.), covering filings from Apr 25, 2025 onwards. 4 of those were filed in the last 90 days.

Are PMCB insiders net buyers or net sellers?

Across the full Form 4 history for PMCB, 6 transactions (25%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does PMCB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is PMCB in?

PharmaCyte Biotech, Inc. (PMCB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.60M.

PMCB insider trading

NasdaqCM Healthcare

PharmaCyte Biotech, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

25% / 0%

Market cap

$7.60M

About PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; license agreements with SG Austria Pte. Ltd.; and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Company website: pharmacyte.com

PMCB insider activity at a glance

FilingIQ has scored 24 insider transactions for PMCB since Apr 25, 2025. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 6 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on PMCB insider trades is 55.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live PMCB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for PMCB?: FilingIQ tracks 24 Form 4 insider transactions for PMCB (PharmaCyte Biotech, Inc.), covering filings from Apr 25, 2025 onwards. 4 of those were filed in the last 90 days.
Are PMCB insiders net buyers or net sellers?: Across the full Form 4 history for PMCB, 6 transactions (25%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does PMCB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is PMCB in?: PharmaCyte Biotech, Inc. (PMCB) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $7.60M.

Methodology & sources

Every PMCB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.